Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Survival outcomes of patients with MCL relative to ibrutinib response.
  • Fig. S2. Tumor cellularity comparison between the ibrutinib-sensitive and ibrutinib-resistant clinical specimens.
  • Fig. S3. DEGs between ibrutinib-sensitive and ibrutinib-resistant tumors using the nanoString nCounter system 63-gene ibrutinib resistance panel.
  • Fig. S4. DEGs between the ibrutinib-sensitive and ibrutinib-resistant tumors using the nanoString nCounter system panCancer panel.
  • Fig. S5. Relative abundance of metabolites in ibrutinib-sensitive and ibrutinib-resistant MCL cell lines.
  • Fig. S6. OXPHOS pathway activation in ibrutinib-resistant MCL cells.
  • Fig. S7. OXPHOS pathway member up-regulation in BTK KD ibrutinib-resistant MCL cell lines.
  • Fig. S8. The growth inhibition effects of rotenone treatment on ibrutinib-resistant MCL cells.
  • Fig. S9. Reductions in mitochondrial activity and ATP production and induction of ROS production in ibrutinib-resistant MCL cells.
  • Fig. S10. Induction of apoptosis in ibrutinib-resistant MCL cells.
  • Fig. S11. The anti-cancer effects of IACS-010759 in an ibrutinib-resistant MCL PDX model.
  • Table S1. Information on the samples used for the nanoString nCounter system assay using the 63-gene ibrutinib resistance panel.
  • Table S2. The IC50 values of ibrutinib across MCL cell lines.
  • References (82, 83)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). The clinical and pathological data of patients with MCL.